Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 12/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831747 | 0.87 | L3MBTL1 (0.41) | TSHRCYP1A2TNFL3MBTL1RAB9A | |
| SCHEMBL10867514 | 0.82 | CYP1A2 (0.44) | TSHRCYP1A2TNFL3MBTL1RAB9A | |
| SCHEMBL10084759 | 0.81 | CYP1A2 (0.50) | TSHRCYP1A2TNFL3MBTL1RAB9A | |
| SCHEMBL1855324 | 0.81 | CYP1A2 (0.53) | TSHRCYP1A2L3MBTL1RAB9A | |
| SCHEMBL27711788 | 0.81 | THRB (0.45) | TSHRCYP1A2L3MBTL1 | |
| SCHEMBL856060 | 0.80 | CYP1A2 (0.56) | TSHRCYP1A2L3MBTL1RAB9A | |
| SCHEMBL1863035 | 0.80 | CYP1A2 (0.56) | TSHRCYP1A2L3MBTL1RAB9A | |
| Bromide SCHEMBL741360 | 0.79 | CYP1A2 (0.55) | TSHRCYP1A2L3MBTL1RAB9A | |
| SCHEMBL11861074 | 0.78 | CYP1A2 (0.53) | TSHRCYP1A2TNFL3MBTL1RAB9A | |
| SCHEMBL24757426 | 0.77 | CYP1A2 (0.48) | TSHRCYP1A2L3MBTL1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |